SciELO - Scientific Electronic Library Online

vol.23 issue4Clinical profile of elder patients attending an outpatient setting of a general hospital author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Revista Medica Herediana

Print version ISSN 1018-130X


UNTAMA, José  and  DEL CARPIO, Daniel. Effect of an anti CD20 monoclonal antibody (Rituximab) in immune thrombocytopenia. Rev Med Hered [online]. 2012, vol.23, n.4, pp.223-228. ISSN 1018-130X.

Objectives: To describe the therapeutic response of an anti CD20 monoclonal antibody (Rituximab) in patients with immune thrombocytopenia (ITT). Methods: Retrospective, descriptive and observational case series. The clinical charts of ambulatory patients with ITT who received Rituximab from December 2005 to December 2010 were reviewed. Response was defined as platelet count > 30 thousand, at least duplicate the initial platelet count and no evidence of bleeding, and complete response was defined as platelet count > 100 thousand and no evidence of bleeding. Results: 24 courses of treatment were evaluated. Response was obtained in 18 patients (75%); mean time to response was 11.9 weeks (range: 0,7 to 37.4); mean duration of response was 16 months (range: 3.3 to 55.3); 12 patients remained with the achieved response during a mean follow up of 22 months (range: 2.3 to 25.2). Complete response was obtained in 13/23 cases (60%); mean time to response was 17 weeks (range: 0.7 to 62,3); mean duration of response was 10,1 months (range: 2.3 to 25.2); 5 patients remained with complete response after a follow up of 20 months (range: 8-29). Conclusions: A high response rate was achieved with Rituximab (75%) in patients with ITT who had failed at least to one treatment.

Keywords : CD20 antigens; purpura; thrombocytopenic; idiopathic.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )